Overview

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with multiple myeloma (MM).
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center